-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Background and targets are reported to have similar course of COVID-19 in patients with inflammatory bowel disease (IBD) and in the general population.
, however, it is not clear how likely IBD patients are to develop new coronary pneumonia.
this prospective observational study, the researchers aimed to determine the rate of SARS-CoV2 infection in IBD patients treated with biotherapy.
method researchers evaluated the presence of antibodies in 354 serums from IBD patients receiving biological treatment in three different regions of Italy and Germany.
control groups were: i) healthy subjects who were age-matched at the same time in Milan, Italy;
354 patients tested positive for SARS-CoV2 IgG antibodies (prevalence 2.3%).
percentage of IgG-positive patients recruited from Milan is significantly higher than that of IgG patients recruited from other regions (prevalence rate 5.4% VS 0.4%, p -lt;0.005).
IgG-positive patients reported significantly higher rates of fever, insomnia and hearing abnormalities, and were more likely to have close contact with COVID-19-positive subjects before participating in the study.
that the SARS-CoV2 serotony positive in IBD patients treated with biotherapy reflected measurements from the local general population.
specific symptoms and history of exposure associated with SARS-CoV2 strongly increased the likelihood of SARS-CoV2 sero-positive.
biologics are not a risk factor for infection with the new crown in IBD patients.